Treatment Of Ilds And Assessment Research Paper

PAGES
4
WORDS
1247
Cite

Interstitial lung disease is a blanket term for a big group of disorders categorized by progressive scarring of both the lung tissue supporting and between the air sacs. This tissue is called the interstitium. The interstitium consists of the region between the alveolar space and the capillaries. The scarring causes inflammation and damage in the lung tissue followed by lung stiffness, meaning the air sacs cannot expand as much as before. Lung stiffness makes it harder to breathe. People affected by the condition are not able to get enough oxygen from the lungs into their bloodstream. Although some potential causes have been researched, there may be no underlying cause for development of interstitial lung disease. If there is no known cause, it is called idiopathic interstitial lung disease. IPF or idiopathic pulmonary fibrosis remains the most common type of this illness. Of the causes most widely recognized, cigarette smoking is said to potentially make the disease more severe and the progression and onset more rapid. Although there are treatments, once lung scarring begins there is no means of reversing the damage.

Symptoms vary, but generally include a dry cough as well as shortness of breath either from after exertion or at rest. Other symptoms are often restricted to the respiratory tract. The condition is long-term lasting years or for some, can be lifelong. People most affected by the disorder is anyone over the age of 19 with many experiencing it after the age of 60. While it is a rare disorder, there are 200,000 cases reported annually in the United States. When people with a disease that falls within this category undergo physical examination, they will typically have bilateral inspiratory fine crackles. These are seen clearly seen at the lung bases. What should not be expected when examining is expiratory wheezing as it is relatively uncommon. If any skin rashes or joint deformities are present, this may signal underlying connective tissue...

...

Some people develop it just from injuring the lungs and healing abnormally. Other triggers include autoimmune diseases, certain medications, exposure to inorganic and organic agents that may happen at home or in the workplace, and some kinds of radiation. When it comes to environmental and occupational factors, certain inorganic and organic materials may cause appearance of interstitial lung disease after long-term exposure.
Such materials are:

1. Asbestos fibers

2. Coal dust

3. Grain dust

4. Silica dust

5. Mold from shower, previous water damage, and hot tubs

6. Bird protein

The list of medications and radiation that could damage the lungs are:

1. Heart medications (Inderal, Innopran, Inderide, Cordarone, Nexterone, Pacerone)

2. Some antibiotics (sulfasalazine and nitrofurantoin)

3. Chemotherapy/immunomodulating drugs (cyclophosphamide and methotrexate)

4. Radiation for breast or lung cancer can lead to damage in the lungs months, even years after the first treatment.

Cigarette smoke can cause lung damage and as previously stated, may accelerate the progression of the lung damage. All these potential causes may not be what causes interstitial lung disease in every patient. Some do not have any known cause.

Some risk factors that may attribute to interstitial lung disease include family history due to some forms of it being heritable, age, degree of exposure to environmental and occupational toxins, smoking, and radiation. Although children and infants are not likely to develop interstitial lung disease, it can happen, but it is very rare. The main cause seems to be exposure to toxins and many cases from the 200,000 diagnosed each year point to these irritants/toxins as being the cause…

Sources Used in Documents:

References

Fischer, A. & du Bois, R. (2012). Interstitial lung disease in connective tissue disorders. The Lancet,380(9842), 689-698. http://dx.doi.org/10.1016/s0140-6736(12)61079-4

Maher, T. (2014). Current and Emerging Treatment Options in Interstitial Lung Disease. Pulmonary Manifestations Of Rheumatic Disease, 193-216. http://dx.doi.org/10.1007/978-1-4939-0770-0_14

Moazedi-Fuerst, F., Kielhauser, S., Brickmann, K., Tripolt, N., Meilinger, M., Lufti, A., & Graninger, W. (2015). Sonographic assessment of interstitial lung disease in patients with rheumatoid arthritis, systemic sclerosis and systemic lupus erythematosus. Clinical And Experimental Rheumatology,33(4 Suppl 91), S87-91. Retrieved from http://europepmc.org/abstract/med/25665185


Cite this Document:

"Treatment Of Ilds And Assessment" (2016, July 18) Retrieved April 19, 2024, from
https://www.paperdue.com/essay/treatment-of-ilds-and-assessment-2161437

"Treatment Of Ilds And Assessment" 18 July 2016. Web.19 April. 2024. <
https://www.paperdue.com/essay/treatment-of-ilds-and-assessment-2161437>

"Treatment Of Ilds And Assessment", 18 July 2016, Accessed.19 April. 2024,
https://www.paperdue.com/essay/treatment-of-ilds-and-assessment-2161437

Related Documents

Chronic Obstructive Pulmonary Disease (COPD) COPD constitutes a major source of mortality and morbidity across the globe, with a considerable economic effect. New GOLD (Global initiative for chronic Obstructive Lung Disease) guidance modifications refined patient classification for therapy by employing spirometry, exacerbation rate and symptom evaluation combined. Therapy attempts at decreasing both extant disease symptoms and vulnerability to adverse health conditions in the future. On account of their established effectiveness, the